Can Fluconazole (Diflucan) Cause Liver Enzyme Elevation?
Yes, fluconazole can cause elevation of liver enzymes, though serious hepatotoxicity is rare. The FDA label explicitly warns that fluconazole has been associated with rare cases of serious hepatic toxicity, with hepatic reactions ranging from mild transient elevations in transaminases to clinical hepatitis, cholestasis, and fulminant hepatic failure, including fatalities 1.
Incidence and Severity
Mild transient elevations in liver transaminases are the most common hepatic manifestation, occurring in approximately 1% of patients receiving fluconazole in clinical trials when transaminases exceed 8 times the upper limit of normal 1.
Overall incidence of acute liver injury with fluconazole is relatively low, with rates of 13.0 events per 1,000 person-years in a large cohort study 2.
Severe acute liver injury (defined as coagulopathy with hyperbilirubinemia) occurs at a rate of only 2.0 events per 1,000 person-years with fluconazole 2.
Acute liver failure is extremely rare but has been documented in case reports, even occurring after short-term use and in patients without pre-existing liver disease 3.
Clinical Characteristics
The hepatotoxicity profile shows important patterns:
No clear dose-relationship: The FDA label notes that no obvious relationship exists between total daily dose, duration of therapy, sex, or age of the patient and the development of hepatotoxicity 1.
Reversibility: Fluconazole hepatotoxicity has usually, but not always, been reversible upon discontinuation of therapy 1.
Time course: Liver enzyme elevations can occur as early as the second day of therapy 4, though they typically develop during longer courses of treatment.
High-Risk Populations
Certain patient groups face substantially elevated risk:
Pre-existing chronic liver disease increases the risk of aminotransferases >200 U/L by 4.68-fold and severe acute liver injury by 5.62-fold 2.
Patients with cirrhosis: In critically ill patients, 77.3% of those with cirrhosis met Drug-Induced Liver Injury Network (DILIN) criteria during fluconazole therapy 5.
HIV-infected patients: Clinical adverse events were reported more frequently in HIV-infected patients (21%) compared to non-HIV infected patients (13%), though the patterns were similar 1. HIV-positive patients may be at particular risk for hepatotoxicity 4.
Patients with serious underlying conditions: Fatal hepatic reactions occurred primarily in patients with serious underlying medical conditions (predominantly AIDS or malignancy) who were often taking multiple concomitant medications 1.
Concomitant hepatotoxic medications: The incidence of abnormally elevated serum transaminases was greater in patients taking fluconazole with rifampin, phenytoin, isoniazid, valproic acid, or oral sulfonylurea hypoglycemic agents 1.
Monitoring Recommendations
Baseline and periodic monitoring of hepatic enzymes is essential:
The IDSA guidelines for histoplasmosis recommend measuring hepatic enzyme levels before therapy and at least at 1,2, and 4 weeks, then every 3 months during azole therapy 6.
The blastomycosis guidelines similarly recommend measuring hepatic enzymes before starting therapy, at least at 2 and 4 weeks after therapy begins, and every 3 months during therapy 7.
Discontinuation criteria: Fluconazole should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to the drug 1.
Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more severe hepatic injury 1.
Clinical Context
Despite the potential for hepatotoxicity, fluconazole remains widely recommended in clinical practice guidelines:
The IDSA candidiasis guidelines recommend fluconazole as a Category 1 (strong evidence) agent for prophylaxis in multiple high-risk populations, including stem cell transplant recipients, patients with chemotherapy-induced neutropenia, and ICU patients 8.
The 2016 IDSA guidelines continue to recommend fluconazole as an alternative agent for candidemia in non-critically ill patients without prior azole exposure 9, 10.
Important Caveats
Weight-based dosing: A study of critically ill patients found that weight-based fluconazole dosing (<6 mg/kg versus ≥6 mg/kg) did not significantly affect the number of patients meeting DILIN criteria for liver injury 5.
DILIN criteria limitations: In critically ill patients, DILIN criteria may overestimate the incidence of fluconazole-associated liver injury, as only 14.5% of patients meeting DILIN criteria also met the definition for hepatocellular damage 5.
Comparison to other azoles: Fluconazole has lower rates of acute liver injury compared to voriconazole (181.9 events/1000 person-years) and posaconazole (191.1 events/1000 person-years), though these agents are used in different clinical contexts 2.